These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 3126081

  • 21. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I.
    Lethagen S, Harris AS, Nilsson IM.
    Blut; 1990 Mar; 60(3):187-91. PubMed ID: 2107887
    [Abstract] [Full Text] [Related]

  • 22. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders.
    Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP.
    Br J Haematol; 2000 Jun; 109(4):865-9. PubMed ID: 10929043
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy.
    Vinayagam S, Simons LR, Chowdary P, Thurlow P, Brooks SV, Riddell AF.
    Haemophilia; 2014 Jul; 20(4):e304-10. PubMed ID: 24758424
    [Abstract] [Full Text] [Related]

  • 24. Mild forms of von Willebrand disease: diagnosis and management.
    Federici AB.
    Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 27. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ, Casanova R.
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [Abstract] [Full Text] [Related]

  • 28. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 29. Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
    Chandrakumaran P, Hews-Girard J, Poon MC.
    Haemophilia; 2023 Jul; 29(4):1095-1103. PubMed ID: 37257847
    [Abstract] [Full Text] [Related]

  • 30. Platelet--von Willebrand factor interactions in type IIB von Willebrand's disease.
    Holmberg L, Kristoffersson AC, Lamme S, Nilsson IM, Awidi A, Solum NO.
    Scand J Haematol; 1985 Sep; 35(3):305-14. PubMed ID: 3877338
    [Abstract] [Full Text] [Related]

  • 31. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
    Federici AB.
    Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
    [Abstract] [Full Text] [Related]

  • 32. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease.
    Revel-Vilk S, Schmugge M, Carcao MD, Blanchette P, Rand ML, Blanchette VS.
    J Pediatr Hematol Oncol; 2003 Nov; 25(11):874-9. PubMed ID: 14608197
    [Abstract] [Full Text] [Related]

  • 33. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S, Mezzasoma AM, Leone M, Gresele P.
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The role of the spleen in regulating the plasma levels of factor VIII--von Willebrand's factor after DDAVP.
    Garcia VV, Coppola R, Mannucci PM.
    Blood; 1982 Dec; 60(6):1402-6. PubMed ID: 6814552
    [Abstract] [Full Text] [Related]

  • 36. von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma.
    Holmberg L, Berntorp E, Donnér M, Nilsson IM.
    Blood; 1986 Sep; 68(3):668-72. PubMed ID: 3488775
    [Abstract] [Full Text] [Related]

  • 37. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.
    Acta Haematol; 2009 Sep; 121(2-3):119-27. PubMed ID: 19506358
    [Abstract] [Full Text] [Related]

  • 38. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor.
    Cattaneo M, Moia M, Delle Valle P, Castellana P, Mannucci PM.
    Blood; 1989 Nov 01; 74(6):1972-5. PubMed ID: 2508791
    [Abstract] [Full Text] [Related]

  • 39. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M, Simoni L, Gringeri A, Mannucci PM.
    Br J Haematol; 1994 Feb 01; 86(2):333-7. PubMed ID: 8199023
    [Abstract] [Full Text] [Related]

  • 40. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.
    Mohri H, Hashimoto Y, Yamazaki E, Kanamori H, Okubo T.
    Hematopathol Mol Hematol; 1998 Feb 01; 11(2):109-15. PubMed ID: 9608359
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.